Effect of intravitreal injections on the progression and prognosis of primary open-angle glaucoma
DOI: 10.32364/2311-7729-2021-21-4-227-234
A.B. Movsisyan1,2, N.G. Glazko1, A.Yu. Brezhnev3, A.V. Kuroyedov2,4
1Hospital for War Veterans No. 2, Moscow, Russian Federation
2Pirogov Russian National Research Medical University, Moscow, Russian Federation
3Kursk State Medical University, Kursk, Russian Federation
4P.V. Mandryka Military Clinical Hospital, Moscow, Russian Federation
Intravitreal injections (IVI) have revolutionized management strategies for many disorders, e.g., age-related macular degeneration (AMD), diabetic macular edema, retinal vein occlusion, choroidal inflammatory diseases, and pathologic myopia. Over the last two decades, exponential growth in the rate of IVIs has been seen worldwide. Primary therapeutic modalities include the courses of periodic injections to achieve and maintain the desired effect. Studies on the effects and neuroprotective role of vascular endothelial growth factor (VEGF) and agents blocking its action in various organs and tissues on the retina have demonstrated some differences in the outcomes and their interpretation which potentially affect IVI management strategy and treatment efficacy. Understanding the results and ocular changes in response to therapy (particularly in patients with glaucoma) requires special attention. A predicted increase in life expectancy and the number of patients with glaucoma sugge sts that the number of patients with several eye diseases who require IVIs will inevitably increase. In addition, some studies evaluate glaucoma progression after IVIs. Considering a lack of relevant data on long-term adverse effects on IOP level and cup area, and improvement of visual functions, IVIs are regarded as a safe treatment modality in patients with primary open-angle glaucoma (POAG) and ocular comorbidities that require IVIs.
Keywords: intravitreal injections, glaucoma, vascular endothelial growth factor, retinal ganglionic cells, retinal nerve fiber layer, intraocular pressure, optical coherence tomography, optic disc.
For citation: Movsisyan A.B., Glazko N.G., Brezhnev A.Yu., Kuroyedov A.V. Effect of intravitreal injections on the progression and prognosis of primary open-angle glaucoma. Russian Journal of Clinical Ophthalmology. 2021;21(4):227–234 (in Russ.). DOI: 10.32364/2311-7729-2021-21-4-227-234.
References
1. Grzybowski A., Told R., Sacu S. et al. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239:181–193. DOI: 10.1159/000486145.
2. Ramulu P.Y., Do D.V., Corcoran K.J. et al. Use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128:335–1340.
3. Peyman G.A., Lad E.M., Moshfeghi D.M. Intravitreal injection of therapeutic agents. Retina. 2009;29:875–912.
4. Campochiaro P.A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81. DOI: 10.1016/j.preteyeres.2015.06.002.
5. Senger D.R., Davis G.E. Angiogenesis. Cold Spring Harb Perspect Biol. 2011;3(8):a005090–a005090. DOI: 10.1101/cshperspect.a005090.
6. Chalam K.V., Brar V.S., Murthy R.K. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol. 2014;132(11):1350–1354. DOI: 10.1001/jamaophthalmol.2014.2356.
7. Kaur C., Foulds W.S., Ling E.A. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol. 2008;2(4):879–889. DOI: 10.2147/OPTH.S3361.
8. Foxton R.H., Finkelstein A., Vijay S. et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013;182:1379–1390. DOI: 10.1016/j.ajpath.2012.12.032.
9. Louissaint A., Rao S., Leventhal C., Goldman S.A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron. 2002;34:945–960.
10. Jin K.L., Zhu Y., Sun Y. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 2002;99:11946–11950.
11. Khaibullina A.A., Rosenstein J.M., Krum J.M. Vascular endothelial growth factor promotes neurite maturation in primary CNS neuronal cultures. Brain Res. Mol. Brain Res. 2004;148:59–68.
12. Rosenstein J.M., Mani N., Khaibullina A., Krum J. M. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J. Neurosci. 2003;23:11036–11044.
13. Krupinski J., Kaluza J., Kumar P. et al. Prognostic value of blood vessel density in ischaemic stroke. Lancet. 1993;342(8873):742.
14. Marti H.J., Bernaudin M., Bellail A. et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 2000;156(3):965–976.
15. Ohab J.J., Fleming S., Blesch A., Carmichael S.T. A neurovascular niche for neurogenesis after stroke. J. Neurosci.: Off. J. Soc. Neurosci. 2006;26(50):13007–13016.
16. Thored P., Wood J., Arvidsson A. at al. O. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke. 2007;38(11):3032–3039.
17. Manoonkitiwongsa P.S., Schultz R.L., McCreery D.B. еt al. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. Journal of Cerebral Blood Flow and Metabolism. 2004;24:693–702.
18. Kitagawa H., Hayashi T., Mitsumoto Y. et al. Reduction of ischemic brain injury by topical application of glial cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. Stroke.1998;29(7):1417–1422.
19. Hu D.N., Ritch R., Liebmann J. et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J. Glaucoma. 2002;11:406–410.
20. Tripathi R.C., Li J., Tripathi B.J. et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–237.
21. Zhou M., Chen S., Wang W. et al. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest. Ophthalmol. Vis. Sci. 2013;54:3874–3879.
22. Chen S., Huang W., Wang J. et al. Soluble CD44 and vascular endothelial growth factor levels in patients with acute primary angle closure. Acta Ophthalmologica. 2015;93(4):261–265.
23. Huang W., Chen S., Gao X. et al. Vascular Endothelial Growth Factor is Increased in Aqueous Humor of Acute Primary Angle-Closure Eyes. J. Glaucoma. 2016;25(7):647–651.
24. Kong X., Liu X, Huang X. et al. Damage to the blood-aqueous barrier in eyes with primary angle closure glaucoma. Mol. Vis. 2010;16:2026–2032.
25. Wang J., Gao X., Du S., Li X. et al. Aqueous humor concentration of VEGF and retinal oxygen saturation after unilateral acute primary angle closure. Acta Ophthalmologica. 2016;94(4):380–385.
26. Kilic U., Kilic E., Jarve A. et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J. Neurosci. 2006;2:12439–12446.
27. Foxton R., Osborne A., Martin K.R. et al. Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism. Cell Death Dis. 2016;7(5):e2212. DOI: 10.1038/cddis.2016.110.
28. Park H.Y., Kim J.H., Park C.K. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol. 2014;184(6):1752–1762. DOI: 10.1016/j.ajpath.2014.02.016.
29. Froger N., Matonti F., Roubeix C. et al. VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci Rep. 2020;10(1):12409. DOI: 10.1038/s41598-020-68488-z.
30. Griffith J.F., Goldberg J.L. Prevalence of comorbid retinal disease in patients with glaucoma at an academic medical center. Clin Ophthalmol. 2015;9:1275–1284. DOI: 10.2147/OPTH.S85851.
31. Brown D.M., Kaiser P.K., Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355(14):1432–1444.
32. Rosenfeld P.J., Brown D.M., Heier J.S. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355(4):1419–1431.
33. Алпатов С.А. Блокаторы ангиогенеза в лечении глазных заболеваний. РМЖ. Клиническая офтальмология. 2015;15(4):196–200. [Alpatov S.A. Angiogenesis inhibitors in treatment of eye diseases. RMJ. Clinical ophthalomology. 2015;15(4):196–200 (in Russ.)].
34. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.F. et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.
35. Carrasco J., Pietsch G.A., Nicolas M.P. et al. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. Adv Ther. 2020;37(1):300–315. DOI: 10.1007/s12325-019-01147-6.
36. Holz F.G., Tadayoni R., Beatty S. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. DOI: 10.1136/bjophthalmol-2014-305327.
37. Holz F.G., Tadayoni R., Beatty S. et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study [published correction appears in Eye (Lond). 2017 Jan;31(1):166]. Eye (Lond). 2016;30(8):1063–1071. DOI: 10.1038/eye.2016.90.
38. Patel A.V., Barb S.M., Young L.H. Finding the Optimal Treatment Plan for Exudative AMD: A review of Current Anti-VEGF Dosing Regimens. Int Ophthalmol Clin. 2015;55(4):103–112. DOI: 10.1097/IIO.0000000000000080.
39. Holz F.G., Amoaku W., Donate J. et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663–671. DOI: 10.1016/j.ophtha.2010.12.019.
40. Lanzetta P., Loewenstein A. Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259–1273. DOI: 10.1007/s00417-017-3647-4.
41. Ohji M., Takahashi K., Okada A.A. et al. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. Adv Ther. 2020;37(3):1173–1187. DOI: 10.1007/s12325-020-01236-x.
42. Kertes P.J., Galic I.J., Greve M. et al. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2020;138(3):244–250. DOI: 10.1001/jamaophthalmol.2019.5540.
43. Fauser S., Muether P.S. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100(11):1494–1498. DOI: 10.1136/bjophthalmol-2015-308264.
44. Nguyen Q.D., Das A., Do D.V. et al. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(7):963–976. DOI: 10.1016/j.ophtha.2019.12.031.
45. Dugel P.U., Singh R.P., Koh A. et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89–99. DOI: 10.1016/j.ophtha.2020.06.028.
46. Lashay A., Riazi-Esfahani H., Mirghorbani M., Yaseri M. Intravitreal Medications for Retinal Vein Occlusion: Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2019;14(3):336–366. DOI: 10.18502/jovr.v14i3.4791.
47. Nalçacı S., Akkın C., Afrashi F. Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy. Turk J Ophthalmol. 2019;49(2):73–77. DOI: 10.4274/tjo.galenos.2018.84665.
48. Zur D., Iglicki M., Loewenstein A. The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Res. 2019;62:231–236. DOI: 10.1159/000499540.
49. Browning D.J., Stewart M.W., Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018;66(12):1736–1750. DOI: 10.4103/ijo.IJO_1240_18.
50. Maturi R.K., Glassman A.R., Liu D. et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018;136(1):29–38. DOI: 10.1001/jamaophthalmol.2017.4914.
51. (Электронный ресурс.) URL https://www.who.int/docs/default-source/decade-of-healthy-ageing/full-decade-proposal/decade-proposal-fulldraft-ru.pdf?sfvrsn=ccd95796_8 (access date: 26.04.2021).
52. Национальное руководство по глаукоме для практикующих врачей. Под ред. Е.А. Егорова, В.П. Еричева. М.: ГЭОТАР-Медиа; 2019:384. [National glaucoma guidelines for practitioners. Editors E.A. Egorov, V.P. Erichev. M.: GEOTAR-Media; 2019:384 (in Russ.)].
53. Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years: evaluating the prevalence of avoidable blindness in relation to "VISION 2020: the Right to Sight". Lancet Global Health. 2020. DOI: 10.1016/S2214-109X(20)30489-7.
54. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th ed. Savona, Italy: PubliComm. 2020:172.
55. Егоров Е.А., Брежнев А.Ю., Егоров А.Е. Нейропротекция при глаукоме: современные возможности и перспективы. РМЖ. Клиническая офтальмология. 2014;4(2):108–112. [Egorov E.A., Brezhnev A.Yu., Egorov A.E. Neuroprotection in glaucoma: current opportunities and future prospects. Literature review. RMJ. Clinical ophthalomology. 2014;4(2):108–112 (in Russ.)].
56. Куроедов А.В., Захарова М.А., Гапонько О.В., Городничий В.В. Влияние интравитреального введения anti-VEGF препаратов на показатели офтальмотонуса у пациентов с классическими и скрытыми хориоидальными неоваскулярными мембранами. РМЖ. Клиническая офтальмология. 2018;19(2):102–106. DOI: 10.21689/2311-7729-2018-18-2-102-106. [Kuroyedov A.V., Zakharova M.A., Gaponko O.V., Gorodnichy V.V. The effect of intravitreal injection of anti-VEGF drugs on the ophthalmotonus values in patients with classic and occult choroidal neovascularization. RMJ. Clinical ophthalmology. 2018;2:102–106 (in Russ.)].
57. Аветисов С.Э., Еричев В.П., Будзинская М.В. и др. Возрастная макулярная дегенерация и глаукома: мониторинг внутриглазного давления после интравитреальных инъекций. Вестник офтальмологии. 2012;128(6):3–5. [Avetisov S.E., Erichev V.P., Boudzinskaya M.V. et al. Age-related macular degeneration and glaucoma: intraocular pressure monitoring after intravitreal injections. Vestnik oftal’mologii. 2012;128(6):3–5 (in Russ.)].
58. Salman A.G. Intrasilicone bevacizumab injection for iris neovascularization after vitrectomy for proliferative diabetic retinopathy. Ophthalmic Res. 2013;49(1):20–24.
59. Rodrigues G.B., Abe R.Y., Zangalli C., Sodre S.L. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016; 2:26. DOI: 10.1186/s40942-016-0051-x.
60. Ермолаев А.П., Першин Б.С., Сургуч В.К. Влияние интравитреального введения дополнительного объема жидкости на внутриглазное давление. Вестник РУДН. 2010;3:64–67. [Ermolaev A.P., Pershin B.S., Surguch V.K. Impact of intravitreous injection of additional volume of liquid on intraocular pressure. RUDN Journal of medicine. 2010;3:64–67 (In Russ.)].
61. Иошин И.Э., Толчинская А.И. Аналоги простагландинов при факоэмульсификации катаракты на фоне первичной глаукомы. РМЖ. Клиническая офтальмология. 2016;4:185–191. [Ioshin I.E., Tolchinskaya A.I. Prostaglandin analogues in cataract surgery by phacoemulsification in patients with primary glaucoma. RMJ. Clinical ophthalmology. 2016;4:185–191 (in Russ.)].
62. Григорьева Н.Н., Шадричев Ф.Е., Шкляров Е.Б. К вопросу о влиянии латанопроста на риск развития макулярного отека у больных сахарным диабетом 2 типа. Офтальмологические ведомости. 2009;2(4):70–73. [Grigoryeva N.N., Shadrichev F.E., Shklyarov E.B. On the effect of latanoprost on the risk of macular edema development in patients with type 2 diabetes. Oftal’mologicheskiye vedomosti. 2009;2(4):70–73 (in Russ.)].
63. Егорова А.В., Васильев А.В., Егоров В.В. Анализ случаев макулярного отека, ассоциированного с применением аналогов простагландинов у больных с ПОУГ в раннем послеоперационном периоде факоэмульсификации возрастной катаракты. Современные технологии в офтальмологии. 2017;2:102–104. [Egorova A.V., Vasiliev A.V., Egorov V.V. Analysis of cases of macular edema associated with the use of prostaglandin analogues in patients with POAG in the early postoperative period of phacoemulsification of age-related cataracts. Modern technologies in ophthalmology. 2017;2:102–104 (in Russ.)].
64. Zarranz-Ventura J., Sala-Puigdollers A., Velazquez-Villoria D. at al. Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. PLoS One. 2019;14(1):e0209997. DOI: 10.1371/journal.pone.0209997.
65. Reid G.A., Sahota D.S., Sarhan M. Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina. 2015;35(8):1647–1655. DOI: 10.1097/IAE.0000000000000524.
66. Du J., Patrie J.T., Prum B.E. et al. Response to: Effects of Intravitreal Anti-VEGF Therapy on Glaucoma-like Progression in Susceptible Eyes. J Glaucoma. 2020;29(6):e55. DOI: 10.1097/IJG.0000000000001500.
67. Agard E., Elchehab H., Ract-Madoux G. et al. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol. 2015;50(2):127–31.DOI: 10.1016/j.jcjo.2014.11.004.
68. Choi M.Y., Kwon J.-W. Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema. Sci Rep. 2020;10(1):13736. DOI: 10.1038/s41598-020-70833-1.
69. Pelegrín L., de la Maza M.S., Molins B. et al. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond). 2015;29(7):943–950. DOI: 10.1038/eye.2015.73.
70. Boland M.V., Ervin A.M., Friedman D.S. et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:271–279. DOI: 10.7326/0003-4819-158-4-201302190-00008.
71. Seth R.K., Salim S., Shields M.B., Adelman R.A. Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. Retina. 2009;29(7):956–959. DOI: 10.1097/IAE.0b013e3181a91dfd.
72. Horsley M.B., Mandava N., Maycotte M.A., Kahook M.Y. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150(4):558–561. DOI: 10.1016/j.ajo.2010.04.029.
73. Nuesi R., Swaminathan S.S. Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes. Curr Ophthalmol Rep. 2020;8(3):111–119. DOI: 10.1007/s40135-020-00235-z.
74. Froger N., Matonti F., Roubeix C. et al. VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci Rep.2020;10(1):12409. DOI: 10.1038/s41598-020-68488-z.
75. Онуфрийчук О.Н., Авдеев Р.В., Александров А.С. и др. Морфофункциональные изменения макулярной области сетчатки при «сухой» форме возрастной макулодистрофии (обзор). РМЖ. Клиническая офтальмология. 2013;13(3):123–130. [Onufriychuk O.N., Avdeyev R.V., Aleksandrov A.S. et al. Morphofunctional retinal changes in patients with non-neovascular age-related macular degeneration (literal review). Clinical ophthalmology. 2013;13(3):123–130 (in Russ.)].
76. Авдеев Р.В., Александров А.С., Басинский А.С. и др. Многоцентровое исследование по определению структурно-функционального статуса зрительного анализатора при одновременном наличии в глазу глаукомы и возрастной макулодистрофии с выявлением их корреляционных связей и степени взаимного влияния. Офтальмология. Восточная Европа. 2013;4(19):15–25. [Avdeev R.V., Aleksandrov A.S., Basinskii A.S. et al. Multicentre study of morphofunctional status of visual analyzer in simultaneous presence in eye glaucoma and age-related macular degeneration with determination of correlations and connections. Ophthalmology. Eastern Europe. 2013;4:15–26 (in Russ.)].
77. Horsley M.B., Mandava N., Maycotte M.A., Kahook M.Y. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150(4):558–561.e1. DOI: 10.1016/j.ajo.2010.04.029.
78. Martinez-de-la-Casa J.M., Ruiz-Calvo A., Saenz-Frances F. et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012;53:6214–6218.
79. Zayit-Soudry S., Zemel E., Loewenstein A., Perlman I. Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina. 2010;30:671–681.
80. Shin H.J., Shin K.C., Chung H., Kim H.C. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014;55:2403–2411. DOI: 10.1167/iovs.13-13769.
81. Beck M., Munk M.R., Ebneter A. et al. Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2016;167:10–17. DOI: 10.1016/j.ajo.2016.04.003.
82. Kopić A., Biuk D., Barać J. et al. Retinal Nerve Fiber Layer Thickness in glaucoma patients treated with multiple intravitreal anti-VEGF (bevacizumab) injections. Acta Clin Croat. 2017;56:406–414. DOI: 10.20471/acc.2017.56.03.07.
83. Saleh R., Karpe A., Zinkernagel M.S., Munk M.R. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):817–824. DOI: 10.1007/s00417-017-3590-4.
84. Wannamaker K.W., Kenny S., Das R. et al. The effects of temporary intraocular pressure spikes after intravitreal dexamethasone implantation on the retinal nerve fiber layer. Clin Ophthalmol. 2019;13:1079–1086. DOI: 10.2147/OPTH. S201395.
85. Рудько А.С., Будзинская М.В., Андреева И.В. и др. Влияние интравитреальных инъекций ранибизумаба и афлиберцепта на слой нервных волокон сетчатки при сочетании неоваскулярной возрастной макулярной дегенерации и глаукомы. Вестник офтальмологии. 2019;135(5):177–183. DOI: 10.17116/oftalma2019135052177. [Rud’ko A.S., Budzinskaya M.V., Andreeva I.V. Effect of intravitreal injections of ranibizumab and aflibercept on the retinal nerve fiber layer in patients with concomitant neovascular age-related macular degeneration and glaucoma. Vestnik Oftalmologii. 2019;135(5):177–183 (in Russ.)].
86. Gómez-Mariscal M., Puerto B., Muñoz-Negrete F.J. et al. Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF. Graefes Arch Clin Exp Ophthalmol. 2019;257:2221–2231. DOI: 10.1007/s00417-019-04354-7.
87. Lee W.J., Kim Y.K., Kim Y.W. et al. Rate of Macular Ganglion Cell-inner Plexiform Layer Thinning in Glaucomatous Eyes With Vascular Endothelial Growth Factor Inhibition. J Glaucoma. 2017;26(11):980–986. DOI: 10.1097/IJG.0000000000000776.
88. Du J., Patrie J.T., Prum B.E. et al. Effects of Intravitreal Anti-VEGF Therapy on Glaucoma-like Progression in Susceptible Eyes. J Glaucoma. 2019;28(12):1035–1040. DOI: 10.1097/IJG.0000000000001382.
2. Ramulu P.Y., Do D.V., Corcoran K.J. et al. Use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128:335–1340.
3. Peyman G.A., Lad E.M., Moshfeghi D.M. Intravitreal injection of therapeutic agents. Retina. 2009;29:875–912.
4. Campochiaro P.A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81. DOI: 10.1016/j.preteyeres.2015.06.002.
5. Senger D.R., Davis G.E. Angiogenesis. Cold Spring Harb Perspect Biol. 2011;3(8):a005090–a005090. DOI: 10.1101/cshperspect.a005090.
6. Chalam K.V., Brar V.S., Murthy R.K. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol. 2014;132(11):1350–1354. DOI: 10.1001/jamaophthalmol.2014.2356.
7. Kaur C., Foulds W.S., Ling E.A. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol. 2008;2(4):879–889. DOI: 10.2147/OPTH.S3361.
8. Foxton R.H., Finkelstein A., Vijay S. et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013;182:1379–1390. DOI: 10.1016/j.ajpath.2012.12.032.
9. Louissaint A., Rao S., Leventhal C., Goldman S.A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron. 2002;34:945–960.
10. Jin K.L., Zhu Y., Sun Y. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 2002;99:11946–11950.
11. Khaibullina A.A., Rosenstein J.M., Krum J.M. Vascular endothelial growth factor promotes neurite maturation in primary CNS neuronal cultures. Brain Res. Mol. Brain Res. 2004;148:59–68.
12. Rosenstein J.M., Mani N., Khaibullina A., Krum J. M. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J. Neurosci. 2003;23:11036–11044.
13. Krupinski J., Kaluza J., Kumar P. et al. Prognostic value of blood vessel density in ischaemic stroke. Lancet. 1993;342(8873):742.
14. Marti H.J., Bernaudin M., Bellail A. et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 2000;156(3):965–976.
15. Ohab J.J., Fleming S., Blesch A., Carmichael S.T. A neurovascular niche for neurogenesis after stroke. J. Neurosci.: Off. J. Soc. Neurosci. 2006;26(50):13007–13016.
16. Thored P., Wood J., Arvidsson A. at al. O. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke. 2007;38(11):3032–3039.
17. Manoonkitiwongsa P.S., Schultz R.L., McCreery D.B. еt al. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. Journal of Cerebral Blood Flow and Metabolism. 2004;24:693–702.
18. Kitagawa H., Hayashi T., Mitsumoto Y. et al. Reduction of ischemic brain injury by topical application of glial cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. Stroke.1998;29(7):1417–1422.
19. Hu D.N., Ritch R., Liebmann J. et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J. Glaucoma. 2002;11:406–410.
20. Tripathi R.C., Li J., Tripathi B.J. et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–237.
21. Zhou M., Chen S., Wang W. et al. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest. Ophthalmol. Vis. Sci. 2013;54:3874–3879.
22. Chen S., Huang W., Wang J. et al. Soluble CD44 and vascular endothelial growth factor levels in patients with acute primary angle closure. Acta Ophthalmologica. 2015;93(4):261–265.
23. Huang W., Chen S., Gao X. et al. Vascular Endothelial Growth Factor is Increased in Aqueous Humor of Acute Primary Angle-Closure Eyes. J. Glaucoma. 2016;25(7):647–651.
24. Kong X., Liu X, Huang X. et al. Damage to the blood-aqueous barrier in eyes with primary angle closure glaucoma. Mol. Vis. 2010;16:2026–2032.
25. Wang J., Gao X., Du S., Li X. et al. Aqueous humor concentration of VEGF and retinal oxygen saturation after unilateral acute primary angle closure. Acta Ophthalmologica. 2016;94(4):380–385.
26. Kilic U., Kilic E., Jarve A. et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J. Neurosci. 2006;2:12439–12446.
27. Foxton R., Osborne A., Martin K.R. et al. Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism. Cell Death Dis. 2016;7(5):e2212. DOI: 10.1038/cddis.2016.110.
28. Park H.Y., Kim J.H., Park C.K. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol. 2014;184(6):1752–1762. DOI: 10.1016/j.ajpath.2014.02.016.
29. Froger N., Matonti F., Roubeix C. et al. VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci Rep. 2020;10(1):12409. DOI: 10.1038/s41598-020-68488-z.
30. Griffith J.F., Goldberg J.L. Prevalence of comorbid retinal disease in patients with glaucoma at an academic medical center. Clin Ophthalmol. 2015;9:1275–1284. DOI: 10.2147/OPTH.S85851.
31. Brown D.M., Kaiser P.K., Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355(14):1432–1444.
32. Rosenfeld P.J., Brown D.M., Heier J.S. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355(4):1419–1431.
33. Алпатов С.А. Блокаторы ангиогенеза в лечении глазных заболеваний. РМЖ. Клиническая офтальмология. 2015;15(4):196–200. [Alpatov S.A. Angiogenesis inhibitors in treatment of eye diseases. RMJ. Clinical ophthalomology. 2015;15(4):196–200 (in Russ.)].
34. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.F. et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.
35. Carrasco J., Pietsch G.A., Nicolas M.P. et al. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. Adv Ther. 2020;37(1):300–315. DOI: 10.1007/s12325-019-01147-6.
36. Holz F.G., Tadayoni R., Beatty S. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. DOI: 10.1136/bjophthalmol-2014-305327.
37. Holz F.G., Tadayoni R., Beatty S. et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study [published correction appears in Eye (Lond). 2017 Jan;31(1):166]. Eye (Lond). 2016;30(8):1063–1071. DOI: 10.1038/eye.2016.90.
38. Patel A.V., Barb S.M., Young L.H. Finding the Optimal Treatment Plan for Exudative AMD: A review of Current Anti-VEGF Dosing Regimens. Int Ophthalmol Clin. 2015;55(4):103–112. DOI: 10.1097/IIO.0000000000000080.
39. Holz F.G., Amoaku W., Donate J. et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663–671. DOI: 10.1016/j.ophtha.2010.12.019.
40. Lanzetta P., Loewenstein A. Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259–1273. DOI: 10.1007/s00417-017-3647-4.
41. Ohji M., Takahashi K., Okada A.A. et al. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. Adv Ther. 2020;37(3):1173–1187. DOI: 10.1007/s12325-020-01236-x.
42. Kertes P.J., Galic I.J., Greve M. et al. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2020;138(3):244–250. DOI: 10.1001/jamaophthalmol.2019.5540.
43. Fauser S., Muether P.S. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100(11):1494–1498. DOI: 10.1136/bjophthalmol-2015-308264.
44. Nguyen Q.D., Das A., Do D.V. et al. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(7):963–976. DOI: 10.1016/j.ophtha.2019.12.031.
45. Dugel P.U., Singh R.P., Koh A. et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89–99. DOI: 10.1016/j.ophtha.2020.06.028.
46. Lashay A., Riazi-Esfahani H., Mirghorbani M., Yaseri M. Intravitreal Medications for Retinal Vein Occlusion: Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2019;14(3):336–366. DOI: 10.18502/jovr.v14i3.4791.
47. Nalçacı S., Akkın C., Afrashi F. Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy. Turk J Ophthalmol. 2019;49(2):73–77. DOI: 10.4274/tjo.galenos.2018.84665.
48. Zur D., Iglicki M., Loewenstein A. The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Res. 2019;62:231–236. DOI: 10.1159/000499540.
49. Browning D.J., Stewart M.W., Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018;66(12):1736–1750. DOI: 10.4103/ijo.IJO_1240_18.
50. Maturi R.K., Glassman A.R., Liu D. et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018;136(1):29–38. DOI: 10.1001/jamaophthalmol.2017.4914.
51. (Электронный ресурс.) URL https://www.who.int/docs/default-source/decade-of-healthy-ageing/full-decade-proposal/decade-proposal-fulldraft-ru.pdf?sfvrsn=ccd95796_8 (access date: 26.04.2021).
52. Национальное руководство по глаукоме для практикующих врачей. Под ред. Е.А. Егорова, В.П. Еричева. М.: ГЭОТАР-Медиа; 2019:384. [National glaucoma guidelines for practitioners. Editors E.A. Egorov, V.P. Erichev. M.: GEOTAR-Media; 2019:384 (in Russ.)].
53. Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years: evaluating the prevalence of avoidable blindness in relation to "VISION 2020: the Right to Sight". Lancet Global Health. 2020. DOI: 10.1016/S2214-109X(20)30489-7.
54. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th ed. Savona, Italy: PubliComm. 2020:172.
55. Егоров Е.А., Брежнев А.Ю., Егоров А.Е. Нейропротекция при глаукоме: современные возможности и перспективы. РМЖ. Клиническая офтальмология. 2014;4(2):108–112. [Egorov E.A., Brezhnev A.Yu., Egorov A.E. Neuroprotection in glaucoma: current opportunities and future prospects. Literature review. RMJ. Clinical ophthalomology. 2014;4(2):108–112 (in Russ.)].
56. Куроедов А.В., Захарова М.А., Гапонько О.В., Городничий В.В. Влияние интравитреального введения anti-VEGF препаратов на показатели офтальмотонуса у пациентов с классическими и скрытыми хориоидальными неоваскулярными мембранами. РМЖ. Клиническая офтальмология. 2018;19(2):102–106. DOI: 10.21689/2311-7729-2018-18-2-102-106. [Kuroyedov A.V., Zakharova M.A., Gaponko O.V., Gorodnichy V.V. The effect of intravitreal injection of anti-VEGF drugs on the ophthalmotonus values in patients with classic and occult choroidal neovascularization. RMJ. Clinical ophthalmology. 2018;2:102–106 (in Russ.)].
57. Аветисов С.Э., Еричев В.П., Будзинская М.В. и др. Возрастная макулярная дегенерация и глаукома: мониторинг внутриглазного давления после интравитреальных инъекций. Вестник офтальмологии. 2012;128(6):3–5. [Avetisov S.E., Erichev V.P., Boudzinskaya M.V. et al. Age-related macular degeneration and glaucoma: intraocular pressure monitoring after intravitreal injections. Vestnik oftal’mologii. 2012;128(6):3–5 (in Russ.)].
58. Salman A.G. Intrasilicone bevacizumab injection for iris neovascularization after vitrectomy for proliferative diabetic retinopathy. Ophthalmic Res. 2013;49(1):20–24.
59. Rodrigues G.B., Abe R.Y., Zangalli C., Sodre S.L. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016; 2:26. DOI: 10.1186/s40942-016-0051-x.
60. Ермолаев А.П., Першин Б.С., Сургуч В.К. Влияние интравитреального введения дополнительного объема жидкости на внутриглазное давление. Вестник РУДН. 2010;3:64–67. [Ermolaev A.P., Pershin B.S., Surguch V.K. Impact of intravitreous injection of additional volume of liquid on intraocular pressure. RUDN Journal of medicine. 2010;3:64–67 (In Russ.)].
61. Иошин И.Э., Толчинская А.И. Аналоги простагландинов при факоэмульсификации катаракты на фоне первичной глаукомы. РМЖ. Клиническая офтальмология. 2016;4:185–191. [Ioshin I.E., Tolchinskaya A.I. Prostaglandin analogues in cataract surgery by phacoemulsification in patients with primary glaucoma. RMJ. Clinical ophthalmology. 2016;4:185–191 (in Russ.)].
62. Григорьева Н.Н., Шадричев Ф.Е., Шкляров Е.Б. К вопросу о влиянии латанопроста на риск развития макулярного отека у больных сахарным диабетом 2 типа. Офтальмологические ведомости. 2009;2(4):70–73. [Grigoryeva N.N., Shadrichev F.E., Shklyarov E.B. On the effect of latanoprost on the risk of macular edema development in patients with type 2 diabetes. Oftal’mologicheskiye vedomosti. 2009;2(4):70–73 (in Russ.)].
63. Егорова А.В., Васильев А.В., Егоров В.В. Анализ случаев макулярного отека, ассоциированного с применением аналогов простагландинов у больных с ПОУГ в раннем послеоперационном периоде факоэмульсификации возрастной катаракты. Современные технологии в офтальмологии. 2017;2:102–104. [Egorova A.V., Vasiliev A.V., Egorov V.V. Analysis of cases of macular edema associated with the use of prostaglandin analogues in patients with POAG in the early postoperative period of phacoemulsification of age-related cataracts. Modern technologies in ophthalmology. 2017;2:102–104 (in Russ.)].
64. Zarranz-Ventura J., Sala-Puigdollers A., Velazquez-Villoria D. at al. Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. PLoS One. 2019;14(1):e0209997. DOI: 10.1371/journal.pone.0209997.
65. Reid G.A., Sahota D.S., Sarhan M. Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina. 2015;35(8):1647–1655. DOI: 10.1097/IAE.0000000000000524.
66. Du J., Patrie J.T., Prum B.E. et al. Response to: Effects of Intravitreal Anti-VEGF Therapy on Glaucoma-like Progression in Susceptible Eyes. J Glaucoma. 2020;29(6):e55. DOI: 10.1097/IJG.0000000000001500.
67. Agard E., Elchehab H., Ract-Madoux G. et al. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol. 2015;50(2):127–31.DOI: 10.1016/j.jcjo.2014.11.004.
68. Choi M.Y., Kwon J.-W. Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema. Sci Rep. 2020;10(1):13736. DOI: 10.1038/s41598-020-70833-1.
69. Pelegrín L., de la Maza M.S., Molins B. et al. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond). 2015;29(7):943–950. DOI: 10.1038/eye.2015.73.
70. Boland M.V., Ervin A.M., Friedman D.S. et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:271–279. DOI: 10.7326/0003-4819-158-4-201302190-00008.
71. Seth R.K., Salim S., Shields M.B., Adelman R.A. Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. Retina. 2009;29(7):956–959. DOI: 10.1097/IAE.0b013e3181a91dfd.
72. Horsley M.B., Mandava N., Maycotte M.A., Kahook M.Y. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150(4):558–561. DOI: 10.1016/j.ajo.2010.04.029.
73. Nuesi R., Swaminathan S.S. Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes. Curr Ophthalmol Rep. 2020;8(3):111–119. DOI: 10.1007/s40135-020-00235-z.
74. Froger N., Matonti F., Roubeix C. et al. VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci Rep.2020;10(1):12409. DOI: 10.1038/s41598-020-68488-z.
75. Онуфрийчук О.Н., Авдеев Р.В., Александров А.С. и др. Морфофункциональные изменения макулярной области сетчатки при «сухой» форме возрастной макулодистрофии (обзор). РМЖ. Клиническая офтальмология. 2013;13(3):123–130. [Onufriychuk O.N., Avdeyev R.V., Aleksandrov A.S. et al. Morphofunctional retinal changes in patients with non-neovascular age-related macular degeneration (literal review). Clinical ophthalmology. 2013;13(3):123–130 (in Russ.)].
76. Авдеев Р.В., Александров А.С., Басинский А.С. и др. Многоцентровое исследование по определению структурно-функционального статуса зрительного анализатора при одновременном наличии в глазу глаукомы и возрастной макулодистрофии с выявлением их корреляционных связей и степени взаимного влияния. Офтальмология. Восточная Европа. 2013;4(19):15–25. [Avdeev R.V., Aleksandrov A.S., Basinskii A.S. et al. Multicentre study of morphofunctional status of visual analyzer in simultaneous presence in eye glaucoma and age-related macular degeneration with determination of correlations and connections. Ophthalmology. Eastern Europe. 2013;4:15–26 (in Russ.)].
77. Horsley M.B., Mandava N., Maycotte M.A., Kahook M.Y. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150(4):558–561.e1. DOI: 10.1016/j.ajo.2010.04.029.
78. Martinez-de-la-Casa J.M., Ruiz-Calvo A., Saenz-Frances F. et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012;53:6214–6218.
79. Zayit-Soudry S., Zemel E., Loewenstein A., Perlman I. Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina. 2010;30:671–681.
80. Shin H.J., Shin K.C., Chung H., Kim H.C. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014;55:2403–2411. DOI: 10.1167/iovs.13-13769.
81. Beck M., Munk M.R., Ebneter A. et al. Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2016;167:10–17. DOI: 10.1016/j.ajo.2016.04.003.
82. Kopić A., Biuk D., Barać J. et al. Retinal Nerve Fiber Layer Thickness in glaucoma patients treated with multiple intravitreal anti-VEGF (bevacizumab) injections. Acta Clin Croat. 2017;56:406–414. DOI: 10.20471/acc.2017.56.03.07.
83. Saleh R., Karpe A., Zinkernagel M.S., Munk M.R. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):817–824. DOI: 10.1007/s00417-017-3590-4.
84. Wannamaker K.W., Kenny S., Das R. et al. The effects of temporary intraocular pressure spikes after intravitreal dexamethasone implantation on the retinal nerve fiber layer. Clin Ophthalmol. 2019;13:1079–1086. DOI: 10.2147/OPTH. S201395.
85. Рудько А.С., Будзинская М.В., Андреева И.В. и др. Влияние интравитреальных инъекций ранибизумаба и афлиберцепта на слой нервных волокон сетчатки при сочетании неоваскулярной возрастной макулярной дегенерации и глаукомы. Вестник офтальмологии. 2019;135(5):177–183. DOI: 10.17116/oftalma2019135052177. [Rud’ko A.S., Budzinskaya M.V., Andreeva I.V. Effect of intravitreal injections of ranibizumab and aflibercept on the retinal nerve fiber layer in patients with concomitant neovascular age-related macular degeneration and glaucoma. Vestnik Oftalmologii. 2019;135(5):177–183 (in Russ.)].
86. Gómez-Mariscal M., Puerto B., Muñoz-Negrete F.J. et al. Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF. Graefes Arch Clin Exp Ophthalmol. 2019;257:2221–2231. DOI: 10.1007/s00417-019-04354-7.
87. Lee W.J., Kim Y.K., Kim Y.W. et al. Rate of Macular Ganglion Cell-inner Plexiform Layer Thinning in Glaucomatous Eyes With Vascular Endothelial Growth Factor Inhibition. J Glaucoma. 2017;26(11):980–986. DOI: 10.1097/IJG.0000000000000776.
88. Du J., Patrie J.T., Prum B.E. et al. Effects of Intravitreal Anti-VEGF Therapy on Glaucoma-like Progression in Susceptible Eyes. J Glaucoma. 2019;28(12):1035–1040. DOI: 10.1097/IJG.0000000000001382.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
